MKI67 and breast cancer: The IKWG consensus recently recommended that multigene assays to determine prognosis for patients with ER-positive breast cancer were not needed for those with low (≤5%) or very high (≥30%) Ki67 scores, but that interlaboratory concordance was insufficient for intermediate values to be considered reliable (2).